Antidepressant efficacy screening of novel targets in the chick anxiety-depression model

Behavioural Pharmacology

Volumn 20, Issue 2, 2009, Pages 146-154

  Sufka, Kenneth J ^a   Warnick, Jason E ^b   Pulaski, Cassan N ^a   Slauson, Stephen R ^a   Kim, Young B ^a   Rimoldi, John M ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b ARKANSAS TECH UNIVERSITY   (United States)

Author keywords

Antidepressant screen; Anxiolytic screen; Domestic fowl; Hybrid model; Separation stress

Indexed keywords

3 AMINOPROPYLBUTYLPHOSPHINIC ACID; ANTALARMIN; ANTIDEPRESSANT AGENT; DOV 216303; KETAMINE; MEMANTINE; MIFEPRISTONE; PRASTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHICK; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL MODEL; NONHUMAN; PREDICTIVE VALIDITY; SOCIAL ISOLATION; VOCALIZATION; ANIMAL; CHICKEN; CLINICAL TRIAL; DISEASE MODEL; EVALUATION; MALE; METHODOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; CHICKENS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MALE; VOCALIZATION, ANIMAL;

EID: 66549105501     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32832a8082     Document Type: Article

References (56)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders IV-TR. Washington: American Psychiatric Association.
2. Bachmann CG, Bilang-Bleuel A, De Carli S, Linthorst AC, Reul JM (2005). The selective glucocorticoid receptor antagonist ORG 34116 decreases immobility time in the forced swim test and affects cAMP-responsive element-binding protein phosphorylation in rat brain. Neuroendocrinology81:129-136.
3. Baldwin DS, Evans DL, Hirschfeld RM, Kasper S (2002). Can we distinguish anxiety from depression? Psychopharmacol Bull 36:158-165.
4. Belanoff JK, Rothschild AJ, Cassidy F, De Battista C, Baulieu EE, Schold C, Schatzberg AF (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry52:386-392.
5. Bosker FJ, Westerlnk BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD, et al. (2004). Future antidepressants: what Is in the pipeline and what is missing? CWS Drugs 18:705-732.
6. Dunn AJ, Swierglel AH, de Beaurepalre R (2005). Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29:891-909.
7. Feltenstein MW, Sufka KJ (2008). Development and validation of alternative models of anxiety and depression using domestic fowl. In: Kalueff AV, LaPorte JL, editors. Behavioral models in stress research. New York: Nova Science Publishers, pp. 23-54.
8. Frazier A, Morilak DA (2005). What should animal models of depression model? Neurosci Biobehav Rev 29:515-523.
9. B antagonists. J Med Chem38:3313-3331.
10. B receptor antagonist in clinical trials. Biochem Pharmacol68:1479-1487.
11. Fuchs E, Flügge G (2006). Experimental animal models for the simulation of depression and anxiety. Dialogues Clin Neurosci8: 323-333.
12. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry32:140-144.
13. Green S, Hodges H (1991). Animal models of anxiety. In: Willner P, editor. Behavioral models in psychopharmacology: theoretical, industrial and clinical perspectives. Cambridge: Cambridge University Press, pp. 21-49.
14. Grelner E, Atkinson AJ Jr, Ayala A, Chrousos GP, Contoreggi C, Eckelman WC, et al. (2002). Synthesis of doubly 13C-labelled antalarmin isotopomers for pharmacokinetic studies. J Label Compd Radiopharm 45:637-645.
15. Henn FA, Vollmayr B (2005). Stress models of depression: forming genetically vulnerable strains. Neurosci Biobehav Rev29:700-804.
16. Holsboer F, Ising M (2008). Central CRH system in depression and anxietyevidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol583:350-357.
17. Jutkiewicz EM, Wood SK, Houshyar H, Hsin LW, Rice KC, Woods JH (2005). The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, In the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology180:215-223.
18. Kalueff AV, Wheaton M, Murphy DL (2007). What's wrong with my mouse model? Advances and strategies In animal modeling of anxiety and depression. Behav Brain Res179:1-18.
19. Kalueff AV, LaPorte JL, Murphy DL, Sufka KJ (2008a). Hybridizing behavioral models: a possible solution to some problems in neurophenotyping research? Prog Neuropsychopharmacol Biol Psychiatry 32:1172-1178.
20. Kalueff AV, Ren-Patterson RF, LaPorte JL, Murphy DL (2008b). Domain interplay concept in animal models of neuropsychiatrie disorders: a new strategy for high throughput neurophenotyping research. Behav Brain Res188:243-249.
21. Katz R (1981). Animal models and human depressive disorders. Neurosci Biobehav Rev20:231 -246.
22. Kessler RC, Berglund P, Demleer O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry62:593-602.
23. Korte SM, Boer SF, Kloet ER, Bohus B (1995). Anxiolytlc-like effects of selective mlneralocorticold and glucocorticoid antagonists on fear-enhanced behavior In the elevated plus-maze. Psychoneuroendocrinology20: 385-394.
24. Kos T, Popik P (2005). A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice. Behav Pharmacol16:156-161.
25. Lehr E (1989). Distress call reactivation in isolated chicks: a behavioral indicator with high selectivity for antidepressants. Psychopharmacology97:145-146.
26. Matthews K, Christmas D, Swan J, Sorrell E (2005). Animal models of depression: navigating through the clinical fog. Neurosci Biobehav Rev29:503-513.
27. McArthur R, Borsini F (2006). Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Beh82:436- 452.
28. Melchior CL, Ritzmann RF (1994). Dehydroepiandrosterone is an anxiolytic in mice on the plus maze. Pharmacol Biochem Behav47:437-441.
29. Nielsen DM, Carey GJ, Gold LH (2004). Antldepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol499:135-146.
30. Norman TR, Burrows GD (2007). Emerging treatments for major depression. Expert Rev Neurother7:203-213.
31. Nowak G, Partyka A, Patucha A, Szewczyk B, Wleroñska JM, Dybata M, et al. (2006). Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol 149:581-590.
32. Panksepp J (2003). Can anthropomorphic analyses of separation cries in other animals Inform us about the emotional nature of social loss in humans? Psychol Rev 110:376-388.
33. Panksepp J, Vilberg T, Bean NJ, Coy DH, Kastin AJ (1978). Reduction of distress vocalization in chicks by opiate-like peptides. Brain Res Bull3:663-667.
34. Panksepp J, Meeker R, Bean NJ (1980). The neurochemical control of crying. Pharmacol Biochem Behav12:437-443.
35. Panksepp J, Yates G, Ikemoto S, Nelson E (1991). Simple ethological models of depression: social isolation induced despair in chicks and mice. In: Olivier O, Moss J, Slangen JL, editors. Animal models in psychopharmacology. Basel: Blrkhäuser Verlag, pp.161 -181.
36. Petnehazy I, Jaszay ZM, Szabo A, Everaert K (2003). Convenient one pot synthesis of phosphonites and H-phosphlnates. Synth Commun33:1665- 1674.
37. Pryce CR, Rüedl-Bettschen D, Dettllng AC, Weston A, Russig H, Ferger B, Feldon J (2005). Long-term effects of early-life environmental manipulations in rodents and primates: potential animal models in depression research. Neurosci Biobehav Rev29:649-674.
38. Rivas-Vazquez RA, Saff-Biller D, Ruiz I, Biais MA, Rivas-Vazquez A (2004). Current issues in anxiety and depression: comorbid, mixed, and subthreshold disorders. Prof Psychol Res Pract35:74-83.
39. Rossi J III, Sahley TL, Panksepp J (1983). The role of brain norepinephrine in Clonidine suppression of isolation-induced distress in the domestic chick. Psychopharmacology79:338-342.
40. Russell WMS, Burch RL (1959). The principles of humane experimental technique. London: Methuen.
41. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx2:590- 611.
42. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS (2003). Antidepressant-like actions of DOV 21 947: a triple reuptake Inhibitor. Eur J Pharmacol461:199-104.
43. Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A (2006). Preclinical and clinical pharmacology of DOV 216,303, a triple reuptake inhibitor. CWS Drug Rev12:123-134.
44. Sufka KJ, Feltensteln MW, Warnick JE, Acevedo EO, Webb HE, Cartwright CM (2006). Modeling the anxiety-depression continuum hypothesis in domestic fowl chicks. Behav Pharmacol17:681-689.
45. Van der Staay FJ (2006). Animal models of behavioral dysfunctions: basic concepts and classifications, and an evaluation strategy. Brain Res Rev52:131-159.
46. Veen G, van Vliet IM, de Rijk RH, Zitman FG (2008). Need for alternative ways of phenotyplng of mood, anxiety, and somatoform disorders in biological research. Prog Brain Res167:277-280.
47. Warnick JE, Sufka KJ (2008). Animal models of anxiety: examining their validity, utility and ethical considerations. In: Kalueff AV, LaPorte JL, editors. Behavioral models in stress research. New York: Nova Science Publishers. pp. 55-71.
48. Warnick JE, Wicks RT, Sufka KJ (2006). Modeling anxiety-like states: pharmacological characterization of the chick separation stress paradigm. Behav Pharmacol17:581-587.
49. Warnick JE, Huang C-J, Acevedo EO, Sufka KJ (2009). Modeling the anxiety-depression continuum In chicks. J Psychopharmacol23:143- 166.
50. Watson D (2005). Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSM-V. J Abnorm Psychol114: 522-536.
51. Willner P (1991a). Behavioural models in psychopharmacology. In: Willner P, editor. Behavioral models in psychopharmacology: theoretical, Industrial and clinical perspectives. Cambridge: Cambridge University Press, pp. 3-18.
52. Willner P (1991b). Animal models of depression. In: Willner P, editor. Behavioral models in psychopharmacology: theoretical, Industrial and clinical perspectives. Cambridge: Cambridge University Press, pp. 91-125.
53. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E (1999). Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry156:646-649.
54. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. (2006a). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry63: 856-864.
55. Zarate CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. (2006b). A double-blind, placebo-controlled study of memantlne in the treatment of major depression. Am J Psychiatry163:153-155.
56. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, lsing M, Holsboer F (2000). Effects of the high-affinity corticotrophin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res34:171-181.